It’s only a matter of time before 3D bio-printing really takes off. One of the leaders in the space is Organovo, a company who has already been able to 3D print living liver tissue, and has an ultimate goal of 3D printing a functioning liver for transplantation within a human being.
Before we get there though, there are many useful applications to 3D printed living tissue, which can already be used today. One such application is that of drug discovery testing. Every year billions of dollars are spent performing clinical trials on potential new drugs for the market. Many of these trials involve human beings, oftentimes being put at some risk. Liver toxicity testing, in particular, is usually performed using tissue samples from cadavers, meaning it’s not all that easy to obtain such samples. What 3D bio-printing enables researchers to do, is create live human tissue, which can then be used as a test bed to discover any negative reactions a particular drug may have on that tissue. Once scaled up, such a process could make available as much tissue as is needed for research, as well as tissue of extremely high quality.
Organovo has been leading the way in this space. They have been working for years to perfect the 3D printing techniques required to produce high quality tissue, which is able to stay alive over a long period of time. Today, the company announced an agreement with one of the largest pharmaceutical corporations on the planet, Johnson & Johnson. The actual agreement was signed between Organovo and Janssen Research and Development (JRD), a pharmaceutical company of Johnson & Johnson.
Under this agreement, of which the exact terms have not yet been disclosed, the companies will work together to evaluate the use of 3D bio-printed tissue in a drug discovery setting. Just what kind of tissue, and to what extent the testing will be done, is yet to be seen, however, it certainly bodes well for the progress of 3D bio-printing technology. To have a major, globally recognizable, corporation like Johnson & Johnson on board, could push the adoption of this technology, as well as its progress to a whole to level. It is interesting to note that following the release of an 8K filing disclosing this agreement this morning, shares of Organovo are up over 11%.
What will the implications of this agreement be? Let’s hear your opinions in the Organovo/Johnson & Johnson forum thread on 3DPB.com.
Subscribe to Our Email Newsletter
Stay up-to-date on all the latest news from the 3D printing industry and receive information and offers from third party vendors.
You May Also Like
Bloomberg: 3D Printed Rocket Maker Relativity Space Facing Financial Challenges
According to a recently published article in Bloomberg, the Long Beach-based launch company Relativity Space — one of many entities claiming to have the “world’s largest” metal 3D printer —...
LEAP 71’s AI-Designed Rocket Engine Passes First Hot-Fire Test
Dubai tech-driven space innovator LEAP 71 successfully tested a 3D printed rocket engine designed entirely by an A.I. model called Noyron. This engine, made from copper, was designed autonomously without...
2024 NASA Grants Feature Top 3D Printing Tech
NASA has again proven its commitment to innovation by awarding nearly 250 small business teams funding to develop cutting-edge technologies. This year’s Phase 1 Small Business Innovation Research (SBIR) and...
ISRO Successfully Tests 3D-Printed Liquid Rocket Engine for 665 Seconds
On May 9, 2024, the Indian Space Research Organization (ISRO) successfully conducted a long-duration hot test of a 3D printed liquid rocket engine. The tested engine, known as PS4, is...